E-Mail
Scientists at the Walter Reed Army Institute for Research have shown that microRNA biomarkers related to Alzheimer s disease play a role in brain damage caused by traumatic brain injury.
TBI or brain trauma results from blows to the head, leading to chronic disruption of the brain and a cascade of long-term health conditions. Patients who suffer from TBI are at much higher risk of developing neurodegenerative disease or dementia, particularly Alzheimer s disease. The mechanism behind this relationship remains understudied, making the development effective therapeutics challenging.
MiRNAs are small pieces of genetic material that play a critical role in normal gene expression. Yet, studies have also linked abnormal miRNA levels, or dysregulation, to a range of diseases including neurodegenerative disorders and cell death after TBI, making them a subject of great interest to researchers who hope to use them as biomarkers and novel targets of drug therapies.
DVIDS - News - Army Announces FDA Clearance of Field-Deployable TBI Blood Test
dvidshub.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dvidshub.net Daily Mail and Mail on Sunday newspapers.
评估人士：中国制疫苗巴西后期试验 有效力低于60％
soundofhope.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from soundofhope.org Daily Mail and Mail on Sunday newspapers.
The History of the Forgotten Pandemic
In spring 1957, tens of thousands of refugees in Hong Kong fell ill with a novel strain of the flu. The virus would spread around the world, the first global outbreak since the 1918 flu pandemic and the first test of a fledgling early warning system. More than one million people died, 116,000 of them in the United States. But schooling, shopping, and sporting events went on as normal, and the pandemic has largely faded from public memory. A nurse at Montefiore Hospital in New York City receives a flu vaccination in 1957. Photo: Everett Collection Historical/Alamy Stock Photo.
Share this article
Share this article
PLYMOUTH MEETING, Pa., Jan. 6, 2021 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and HPV-associated diseases, today announced positive efficacy results for an open-label Phase 2 trial of VGX-3100 to treat HPV-16 and HPV-18-associated vulvar dysplasia. A 25% or more reduction in HPV-16/18-associated vulvar HSIL (high-grade squamous intraepithelial lesion) was observed for 63% of trial participants (12 of 19) treated with VGX-3100 at six months post-treatment. Three out of the 20 participants with histology data (15%) resolved their vulvar HSIL and had no HPV-16/18 virus detectable in the healed area. By comparison, the spontaneous resolution of vulvar HSIL caused by HPV-16/18 is estimated to be only 2%. The trial also showed VGX-3100 to be safe and well-tolerated. Based upon these results INOVIO is planning